Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS.

Cancer medicine·2025
Same author

Magnetic Resonance Imaging as a Tool for Monitoring Intratibial Growth of Experimental Prostate Cancer Metastases in Mice.

Methods and protocols·2023
Same author

Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).

Acta oncologica (Stockholm, Sweden)·2023
Same author

Osteoclasts directly influence castration-resistant prostate cancer cells.

Clinical & experimental metastasis·2022
Same author

Androgens, aging, and prostate health.

Reviews in endocrine & metabolic disorders·2022
Same author

Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.

The Journal of urology·2022

関連する実験動画

Updated: Jul 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

前立腺がんは前立腺がんである.

Jan-Erik Damber1, Gunnar Aus

  • 1Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Lancet (London, England)
|May 20, 2008
PubMed
まとめ
この要約は機械生成です。

前立腺がんは一般的な診断ですが,スクリーニングの拡大により,低リスクの症例が多く発見されています. 診断された前立腺がんのほとんどは,生命を脅かすものにはならないため,過剰診断が懸念される.

さらに関連する動画

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

関連する実験動画

Last Updated: Jul 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

科学分野:

  • 腫瘍学 腫瘍学
  • 泌尿器科 泌尿器科とは
  • 公衆衛生は公衆衛生である.

背景:

  • 前立腺がんは,世界で2番目に多く診断される癌であり,男性における癌による死亡の第3の主要な原因です.
  • 陽性な家族歴は,年齢や民族性とともに,重要なリスク因子です.
  • アンドロゲン欠乏症のような現在の治療法は短期的に有効ですが,しばしば治癒不可能な再発につながります.

研究 の 目的:

  • 前立腺がんの発生率と死亡率の動向を分析する.
  • スクリーニングと診断の進歩の影響を評価する.
  • 低リスク前立腺がんの進行率を評価する.

主な方法:

  • 前立腺がんの発生率と死亡率に関する疫学データのレビュー.
  • PSAスクリーニングおよび生検技術を含む診断に影響を与える要因の分析.
  • 進行前立腺がんにおける治療結果と再発率の評価.

主要な成果:

  • 前立腺がんの発生率は,スクリーニングと診断の改善により著しく増加しています.
  • 死亡率の動向はそれほど明確ではないが,一部の国では死亡率が安定しているか減少している.
  • 診断された低リスク前立腺がんのわずかな割合は,生命を脅かす段階に進行する.

結論:

  • 発生率の上昇と死亡率の安定/減少の間の格差は,低リスク前立腺がんの過剰診断を示唆しています.
  • スクリーニングと診断の改善は検出率を高めましたが,生存率を比例して改善したわけではありません.
  • 治療戦略を最適化するために,怠惰性の前立腺がんと攻撃性の前立腺がんを区別するためにさらなる研究が必要です.